SCHEMBL3956313

SCHEMBL3956313

Cc1ccc(S(=O)(=O)N2CC2C(=O)NCc2ccccc2)cc1

nearest known ligand 0.62

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.62
FKBP1A P62942 2/20 0.61
PKM P14618 2/20 0.57
CYP3A4 P08684 1/20 0.57
CYP2C9 P11712 1/20 0.57
CYP2C19 P33261 1/20 0.57
L3MBTL1 Q9Y468 2/20 0.56
KMT2A Q03164 2/20 0.56
MEN1 O00255 1/20 0.56
RAB9A P51151 1/20 0.54
MMP1 P03956 2/20 0.54
MMP3 P08254 2/20 0.54
MMP7 P09237 2/20 0.54
MMP9 P14780 2/20 0.54
MMP13 P45452 1/20 0.54
ALDH1A1 P00352 2/20 0.53
MAPT P10636 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4532058 0.84 POLB (0.51) GAAFKBP1AL3MBTL1KMT2AMEN1
SCHEMBL13964823 0.82 ALDH1A1 (0.55) FKBP1APKML3MBTL1KMT2AMEN1
SCHEMBL4032764 0.80 MMP1 (0.62) GAAFKBP1AMMP1MMP3MMP7
SCHEMBL4529431 0.79 MMP2 (0.56) FKBP1AL3MBTL1KMT2AMEN1RAB9A
SCHEMBL15125980 0.78 KMT2A (0.68) GAAFKBP1AL3MBTL1KMT2AMEN1
SCHEMBL13571191 0.78 FKBP1A (0.77) FKBP1AL3MBTL1RAB9AMMP9ALDH1A1
SCHEMBL23630457 0.77 POLB (0.61) GAACYP3A4CYP2C9CYP2C19L3MBTL1
SCHEMBL3832846 0.77 POLB (0.61) GAACYP3A4CYP2C9CYP2C19L3MBTL1
SCHEMBL6097783 0.77 POLB (0.61) GAACYP3A4CYP2C9CYP2C19L3MBTL1
SCHEMBL4035295 0.77 MMP1 (0.60) GAAFKBP1AMMP1MMP3MMP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2099747-A1 RADIOLABELLING VIA FLUORINATION OF AZIRIDINES Bayer Schering Pharma Aktiengesellschaft (DE) 2009-09-16 EP disclosed
US-20090022664-A1 Radiolabelling via fluorination of aziridines BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2009-01-22 US disclosed
US-20090022664-A1 Radiolabelling via fluorination of aziridines BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2009-01-22 US disclosed
US-20090022664-A1 Radiolabelling via fluorination of aziridines BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2009-01-22 US disclosed
WO-2008083729-A1 RADIOLABELLING VIA FLUORINATION OF AZIRIDINES BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-07-17 WO disclosed
WO-2008083729-A1 RADIOLABELLING VIA FLUORINATION OF AZIRIDINES BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-07-17 WO disclosed
EP-1944288-A1 Radiolabelling via fluorination of aziridines Bayer Schering Pharma Aktiengesellschaft (DE) 2008-07-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090022664-A1 Radiolabelling via fluorination of aziridines TMEM14C, ARFGEF1, NPFFR1 GAA 511/4885FKBP1A 4558/4885PKM 2534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.